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Abstract
Background: Window-of-opportunity trials, evaluating the engagement of drugs with their biological target in the
time period between diagnosis and standard-of-care treatment, can help prioritise promising new systemic
treatments for later-phase clinical trials. Renal cell carcinoma (RCC), the 7th commonest solid cancer in the UK,
exhibits targets for multiple new systemic anti-cancer agents including DNA damage response inhibitors, agents
targeting vascular pathways and immune checkpoint inhibitors. Here we present the trial protocol for the WIndow-
of-opportunity clinical trial platform for evaluation of novel treatment strategies in REnal cell cancer (WIRE).
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Methods: WIRE is a Phase II, multi-arm, multi-centre, non-randomised, proof-of-mechanism (single and combination
investigational medicinal product [IMP]), platform trial using a Bayesian adaptive design. The Bayesian adaptive
design leverages outcome information from initial participants during pre-specified interim analyses to determine
and minimise the number of participants required to demonstrate efficacy or futility. Patients with biopsy-proven,
surgically resectable, cT1b+, cN0–1, cM0–1 clear cell RCC and no contraindications to the IMPs are eligible to
participate. Participants undergo diagnostic staging CT and renal mass biopsy followed by treatment in one of the
treatment arms for at least 14 days. Initially, the trial includes five treatment arms with cediranib, cediranib +
olaparib, olaparib, durvalumab and durvalumab + olaparib. Participants undergo a multiparametric MRI before and
after treatment. Vascularised and de-vascularised tissue is collected at surgery. A ≥ 30% increase in CD8+ T-cells on
immunohistochemistry between the screening and nephrectomy is the primary endpoint for durvalumab-
containing arms. Meanwhile, a reduction in tumour vascular permeability measured by Ktrans on dynamic contrast-
enhanced MRI by ≥30% is the primary endpoint for other arms. Secondary outcomes include adverse events and
tumour size change. Exploratory outcomes include biomarkers of drug mechanism and treatment effects in blood,
urine, tissue and imaging.
Discussion: WIRE is the first trial using a window-of-opportunity design to demonstrate pharmacological activity of
novel single and combination treatments in RCC in the pre-surgical space. It will provide rationale for prioritising
promising treatments for later phase trials and support the development of new biomarkers of treatment effect
with its extensive translational agenda.
Trial registration: ClinicalTrials.gov: NCT03741426 / EudraCT: 2018–003056-21.
Keywords: Clinical trial protocol [MeSH], Clear cell renal cell carcinoma [MeSH], Phase II clinical trial [MeSH],
Bayesian adaptive trial, Olaparib [MeSH], Cediranib [MeSH], Durvalumab [MeSH], Window-of-opportunity,
Neoadjuvant therapy [MeSH]
Background
Renal cell carcinoma (RCC) is the 12th commonest solid
cancer globally (> 400,000 cases/year) and the 7th com-
monest in the United Kingdom (~ 14,000 cases/year) [1].
Clear cell RCC (ccRCC), is the commonest histological
subtype found in 75–80% of patients with RCC, and pre-
sents with metastatic disease in 16% of patients [2, 3].
Surgery is the treatment of choice in medically-fit pa-
tients whose disease burden is amenable to resection [4].
Consequently, 56% of patients undergo partial or radical
resection of the tumour-bearing kidney as part of their
treatment [5]. Currently guidelines recommend no peri-
operative treatment in patients undergoing surgery with
curative intent; however, 30% of patients will experience
recurrence [6, 7]. For patients whose disease is not
amenable to surgery, first-line treatment options for
medically fit patients consist of immune-checkpoint in-
hibitors and/or vascular endothelial growth factor
(VEGF) tyrosine kinase inhibitors (TKIs) [8, 9].
The increasing number of possible single-agent and
combination therapeutic options makes it very challen-
ging to prioritise agents in combination for further de-
velopment in large randomised clinical trials. Therefore,
novel trial designs, such as this window-of-opportunity
trial assessing promising new combination treatments in
the period of time between diagnosis and surgery, are re-
quired to determine if the combination results in the
hypothesised mechanistic pharmacology [10]. A further
advantage of the window-of-opportunity design allows
assessing the biological activity of drugs in treatment
naïve patients and ensures that translational analyses are
not biased by previous treatments [10]. In the United
Kingdom, Canada and the United States, patients often
wait 1 month or more between the decision to proceed
with nephrectomy and their surgery [11–13], making a
window-of-opportunity trial design appropriate for the
clinical pathway.
Genomic instability is a hallmark of cancer which
chemo- and radiotherapy exploit while causing signifi-
cant collateral damage to normal tissues [14]. More re-
cently, targeted DNA damage response inhibitors
(DDRi) and immune checkpoint inhibitors have taken
advantage of tumour genomic instability and the result-
ing high mutational burden resulting in higher tumour
specificity and efficacy in a range of different tumour
types [15–17]. DDRi cause synthetic lethality in cells
genetically lacking specific DNA repair mechanisms
[18]. In contrast to this, contextual synthetic lethality oc-
curs synergistically between a pharmacological DDRi
and a second agent [19]. While ccRCC is not commonly
associated with DDR deficiency, recent in-vitro and in-
vivo data demonstrating replication stress as a conse-
quence of common mutations associated with RCC
(VHL loss: 85% of ccRCC, SETD2 mutations: 12% of
ccRCC) and VEGF inhibition suggest that DDR-targeted
treatment may be an effective and relevant therapeutic
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strategy [20, 21]. The initial arms of the WIndow-of-
opportunity clinical trial platform for evaluation of novel
treatment strategies in REnal cell cancer (WIRE) will
evaluate the pharmacological activity of DDRi (Olaparib)
alone and in combination with drug classes well estab-
lished to be active in ccRCC including TKIs (cediranib)
and immune checkpoint inhibitors (durvalumab), in pa-
tients with surgically resectable ccRCC.
Olaparib inhibits poly (ADP-ribose) polymerases (PARP
1–3) which are central to DNA damage repair and gen-
omic stability. It inhibits the repair of single-strand DNA
breaks specifically in cells deficient in homologous recom-
bination, resulting in double strand-breaks, subsequent ac-
cumulation of mutations and cell death [22]. Olaparib has
demonstrated improved progression-free survival (PFS) in
placebo-controlled phase III studies in BRCA-mutated
ovarian cancer [23, 24] and prolonged PFS in a phase III
trial of patients with human epidermal growth factor re-
ceptor 2 (HER2)-negative breast cancer with a germline
BRCA1/2 mutation compared to standard-of-care treat-
ment [16]. In patients with metastatic prostate cancer and
deleterious alterations in genes involved in homologous
recombination repair, olaparib conferred prolonged over-
all survival (OS) and PFS compared to abiraterone or
enzalutamide [25]. Meanwhile, cediranib, a potent VEGF-
A and VEGFR-2 inhibitor causing a significant and rapid
reduction in tumour blood-flow measured by dynamic
contrast-enhanced magnetic resonance imaging (DCE-
MRI), has demonstrated activity against ccRCC among
other cancer types [26–28]. Cediranib in combination
with olaparib improved PFS in ovarian cancer [29]. Given
the replication stress induced by VEGF inhibition, the
combination of cediranib + olaparib was prioritized as a
potential therapeutic strategy for this platform trial [20,
21]. Finally, the immune checkpoint inhibitor durvalumab
prolonged OS in patients with non-small cell lung cancer
undergoing chemoradiotherapy in a placebo-controlled
phase III trial [30]. The established efficacy of PD1/PD-L1
inhibitors in metastatic RCC [31, 32], coupled with in-
creased anti-tumour activity of immune checkpoint inhib-
itors in combination with DDRi, owing to the increased
expression of PD-L1 and activation of the stimulator of
interferon genes (STING) pathway observed pre-clinically,
rationalises this combination treatment [33, 34]. Here we
present the trial protocol for the WIRE trial platform
evaluating these novel treatment strategies in renal cancer




The WIRE trial aims to determine proof-of-mechanism
for several agents (cediranib, olaparib and durvalumab)
used as single or combination therapies by
demonstrating engagement with the expected cellular
pathways. Changes in capillary permeability will be de-
termined in the cediranib, olaparib and cediranib + ola-
parib arms and changes to intra-tumoral CD8+ T-cell
infiltration will be determined in the durvalumab and
durvalumab + olaparib arms.
Secondary objectives
Secondary objectives will aim to investigate the safety of
the investigational medicinal products (IMP) in the pre-
operative period and determine changes in primary
tumour size and overall response measured according to
the Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1 [35]. Where they are not primary
objectives, changes in intratumoral CD8+ T-cells and ca-
pillary permeability will be assessed as secondary
objectives.
Exploratory objectives
Exploratory objectives will aim to define the molecular
biological response to the IMPs for candidate markers of
biological effects in blood, urine, and tissue samples.
Additionally, the relationship of the primary endpoints
with genetic mutations in related genes will be investi-
gated. Finally, the ability of automated histological image
analysis and hyperpolarised [1-13C] pyruvate MRI im-
aging to detect biological treatment response will be
explored.
Trial design and participants
WIRE is a Phase II, multi-arm, multi-centre, non-
randomised, proof-of-mechanism (single and combin-
ation IMPs), platform trial using a Bayesian adaptive de-
sign (ClinicalTrials.gov Identifier: NCT03741426) with
sample size chosen to control frequentist statistical char-
acteristics. It will be conducted at academic medical cen-
tres in the United Kingdom.
The Bayesian adaptive design leverages outcome infor-
mation from initial participants to determine the recruit-
ment target for each treatment arm (see Fig. 1). After
reaching the recruitment target of six participants into
single agent and ten participants into combination treat-
ment arms in the initial stage, recruitment will continue
into subsequent arms until the interim analysis is
complete. Depending on the number of patients achiev-
ing the primary endpoint during these pre-planned in-
terim analyses, the independent data monitoring
committee (IDMC) may close the arm for reaching stat-
istical efficacy or futility. If recruiting additional partici-
pants is likely to confer statistical efficacy, additional
patients will be recruited into an arm until the target for
the second interim analysis is reached. Each arm may
proceed through up to three recruitment stages.
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Potential participants will be identified during multi-
disciplinary team case discussions and invited to partici-
pate in the trial during their standard clinical care visit.
Participants will be provisionally assigned to the cur-
rently recruiting arm and provided a screening identifier.
Upon successfully completing screening, participants will
be allocated a trial identifier and continue with the arm
allocated at screening. Participants may not cross to an-
other arm or enter a reserve pool if they are ineligible
for the current arm.
Eligibility criteria
Key inclusion criteria include age ≥ 18 years, biopsy-
proven, surgically resectable, cT1b+, cN0–1, cM0–1
ccRCC, Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1, at least one measurable le-
sion according to RECIST 1.1, adequate organ and bone
marrow function and contraception. Patients may not
have been exposed to any PARP, tyrosine kinase, im-
mune checkpoint or mammalian target of rapamycin
(mTOR) inhibitors.
Key exclusion criteria include cT1a, N0, M0 ccRCC,
brain metastasis, spinal cord compression unless defin-
itely treated and non-progressive for 28 days and lepto-
meningeal involvement. Furthermore, patients with a
bodyweight ≤30 kg, contraindication for any of the trial
compounds, other invasive malignancy within the last 2
years, concurrent participation in another interventional
clinical trial, cardio- or cerebrovascular complications
within the last 12 months, immunosuppression or active
infection, pregnancy or contraindications for MRI are
excluded from participation. Women of childbearing po-
tential must use two highly effective forms of contracep-
tion from consent until 3 months after the end of the
trial.
Detailed reference values for adequate organ and bone
marrow function as well as in- and exclusion criteria
specific to individual treatment arms can be found in the
Additional file 2.
Informed consent
A trial entrant will provide written informed consent be-
fore any trial-specific intervention in accordance with
the principles of the International Council for Harmon-
isation of Technical Requirements for Pharmaceuticals
for Human Use – Good Clinical Practice (IHC-GCP)
[36]. Translation of the patient information and consent
form will be provided if necessary and trial entrants will
have at least 24 h to consider the patient information
materials. Additional consent for the collection of blood,
urine and tissue samples as well as genetic analyses will
be sought. Consent documents are available in the
Additional file 3.
Fig. 1 Bayesian adaptive trial design with interim analyses and decision boundaries for single-agent and combination-therapy arms. Green arrows
denote efficacy, orange arrows denote futility
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Interventions
Intervention description
This trial includes five sequential treatment arms: 1)
cediranib; 2) cediranib + olaparib; 3) olaparib; 4) durva-
lumab and 5) olaparib + durvalumab. IMPs for the indi-
vidual arms are summarized in Table 1.
Regardless of the treatment arm, patients will undergo
nephrectomy between 17 and 28 days after the first day
of IMP (Fig. 1).
Criteria for discontinuing or modifying allocated
interventions
In the case of toxicity, oral IMPs may be interrupted and
can be dose-reduced as detailed in Table 1. If the tox-
icity persists, the IMP should be discontinued. In the
combination arms, the doses of cediranib and olaparib
will both be reduced unless the toxicity can be attributed
to the toxicity profile of one of the IMPs. In case of dis-
continuation, both IMPs will be discontinued.
Participants will have their IMP discontinued if they
experience unacceptable toxicity despite dose reductions,
disease progression per RECIST 1.1, pregnancy, weight
loss to ≤30 kg or withdraw consent. Participants receiv-
ing olaparib will have their IMP discontinued if they de-
velop myelodysplastic syndrome or acute myeloid
leukemia.
Relevant concomitant care permitted or prohibited during
the trial
All routinely used supportive care will be allowed during
WIRE, except for certain medications prohibited and re-
stricted for safety or efficacy reasons. These are detailed
in the Additional file 2.
Participant timeline




Reduction in tumour vascular permeability by > 30%
measured by median Ktrans on DCE-MRI between the
baseline and pre-surgical MRI will be the primary end-
point for the cediranib, olaparib and cediranib + olaparib
treatment arms. Ktrans is a sensitive and early marker of
response to VEGFR TKI in renal cancer and to olaparib
in ovarian cancer [37, 38]. Additionally, pre-clinical re-
search has demonstrated that the impaired vascular
endothelial cell migration resulting from PARP inhib-
ition has an anti-angiogenic effect [39]. The primary
endpoint for the durvalumab containing arms will be an
increase in CD8+ T-cells on immunohistochemistry
(IHC) assessed by histoscore between the baseline biopsy
and samples taken at nephrectomy. The rationale for
this endpoint is based on evidence in melanoma that an
increased number of tumour infiltrating CD8+ T-cells is
associated with a better response to immune checkpoint
inhibitors [40, 41].
Secondary outcomes
 Adverse events assessed according to the Common
Terminology Criteria for Adverse Events (CTCAE)
Toxicity Criteria (Version 5.0)
 Tumour size change between pre- and post-
treatment MRI
 Tumour response according to RECIST v1.1 on pre-
and post-treatment MRI in participants with M0
disease and pre-and post-treatment contrast-
enhanced CT in participants with M1 disease
 Changes in Ktrans and tumour infiltrating CD8+ T-
cells where these are not primary outcomes
Exploratory outcomes
Exploratory outcomes will include the assessment of
blood, urine, tissue and imaging-based biomarkers of
drug mechanism and treatment response.
Data collection and management
Assessment and collection of outcomes
Primary endpoints will be assessed centrally for all trial
sites when the number of participants required for an in-
terim or final analysis has been reached.
Table 1 Treatment Arms in the WIRE trial. bd: twice daily, IMP: Investigational Medicinal Product, i.v.: intravenous, od: once daily.
Dose reductions permissible in case of toxicity
Arm IMP Dosing, Stopping and Dose Adjustments
1 Cediranib 20 mg oral od, until 36 h before surgery, single reduction to 15 mg od
2 Cediranib +
Olaparib
Cediranib 20 mg oral od and Olaparib 300 mg oral bd, stopping and dose adjustments as in single-agent arms
3 Olaparib 300 mg oral bd, until morning of surgery, two reductions to 250mg bd and 200mg bd
4 Durvalumab 1500 mg i.v. (single infusion)
5 Olaparib +
Durvalumab
Olaparib 300 mg oral bd and Durvalumab 1500 mg i.v. (single infusion). Stopping and dose adjustment for Olaparib as in
single-agent arm above.
bd twice daily, od once daily, i.v. intravenous
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All pseudo-anonymised imaging data will be trans-
ferred to the trial radiologist for the measurement of the
tissue transfer constant Ktrans on DCE-MRI. Following
motion correction, the MiStar software (Apollo Medical,
Melbourne, Australia) will be used for kinetic modelling
of the contrast-enhancement data using the extended
Tofts model [42] and a model arterial input function
[43]. Regions of interest encompassing the entire tumour
will be defined and independently reviewed by two
radiologists. Two radiologists verify the correct record-
ing of the median Ktrans value independently.
The CD8+ T-cell count will be established centrally
following transfer of the formalin-fixed paraffin-
embedded tissue blocks. Following slicing of the block,
endogenous peroxidase suppression and heat-mediated
antigen retrieval, the mouse monoclonal anti-human
CD8 (DAKO Cytomation, Glostrup, Denmark, 1:100 di-
lution) will be the primary antibody. Slides will be
scanned and two board-certified uro-pathologists will
Fig. 2 Timeline of interventions and assessments for the WIRE trial. *Optional, **Only in patients with cM1 disease. US: ultrasound
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quantify the CD8+ T-cells in ten random fields of view
per tumour sample, expressed as the median number of
cells/mm2 before and after treatment.
Participant replacement
Participants will be replaced and not evaluated for the
primary endpoint if they have not received at least 14
days of IMP and/or a single infusion of durvalumab, had
to interrupt the IMP for > 7 consecutive days, had a
compliance rate of < 70% in the 7 days preceding the
pre-surgical imaging, had no pre-surgical imaging or had
surgery more than 28 days after the first day of IMP.
Data management and confidentiality
All trial-related information will be stored securely at
the trial site and transferred pseudo-anonymised
through an encrypted electronic case report form
(eCRF). The eCRF has inbuilt mechanisms to validate
the integrity of data entries. Data will be checked for
clarity, errors and completeness ahead of data export by
two independent staff members. A pseudo-anonymised
copy of imaging data used to obtain the primary end-
point will be retained centrally.
Collection, evaluation and storage of biological specimens
and translational analyses
During screening, patients will undergo urine and blood
collection followed by ultrasound-guided, multi-regional
biopsy of the renal tumour. The biopsy procedure will
be carried out by a consultant interventional radiologist.
Additional blood and urine samples will be collected
after 14 days of IMP and immediately before surgery. At
surgery, samples will be collected from the vascularized
(i.e. during the nephrectomy) and devascularised (i.e.
ex vivo) tumour. 3D-printed, patient-specific tumour
moulds will be used to collect devascularised samples
from locations spatially registered to pre-surgical im-
aging at one of the trial sites. If lesions have a major
axis > 20 cm, biopsies will be taken without the mould.
All trial samples will be stored and analysed in a
pseudo-anonymised manner.
The translational analysis aims to explore potential fu-
ture endpoint markers and determine the response of
molecular markers in DDR-, immune-, apoptosis- and
cell-cycle pathways.
DNA and RNA analyses in tissue, blood and urine will
attempt to explore signatures of response and resistance
to IMPs and confirm the IMP’s mechanism of action.
Additionally, intratumor genetic heterogeneity will be
assessed from multi-regional tumour biopsies and com-
pared to the genetic landscape observed in cell-free
tumour DNA. Furthermore, WIRE aims to investigate
the applicability of the NEAT (N-cadherin, EPCAM,
Age, mTOR) proteomic score [44], which was developed
for survival prediction in patients receiving sunitinib, in
the IMPs under investigation, including the TKI cedira-
nib. WIRE can explore immune- and cytokine-based sig-
natures in peripheral blood mononucleocytes (PBMCs),
plasma or urine which may predict response, resistance,
or toxicity. These will be complemented by metabolo-
mics analyses using mass-spectrometry and nuclear
magnetic resonance on matched biopsy and surgical
tumour tissue pairs, plasma, and urine. Finally, transla-
tional research within WIRE aims to address the unmet
need for new in-vivo and in-vitro models of RCC, gener-
ating reproducible patient-derived xenograft (PDX) and
cell line models to support the rational design of future
therapies.
Statistical methods
Sample size and power
Up to a maximum of 76 evaluable participants will be
recruited into the initial five arms and across all stages.
Monotherapy arms (Arm 1 [Cediranib], Arm 3
[Olaparib], Arm 4 [Durvalumab]) Each monotherapy
arm will enrol a maximum of 12 evaluable participants
with interim analyses after 6 and 9 evaluable participants
have primary outcome data available.
The null hypothesis is 20% or less of participants show
a response on the primary outcome. The alternative hy-
pothesis is that more than 20% of participants show a re-
sponse:H0: p ≤ 0.2 H1: p > 0.2with the power calculated
as the probability of rejecting H0 when p = 0.5.
The IMP will be recommended as promising (null hy-
pothesis rejected) if the arm stops after stage 1 or 2 for
efficacy (see Interim Analyses). If the IMP continues to
stage 3, a p-value will be found by calculating the tail
probability of seeing that many or more responses if the
distribution were binomial with p = 0.2. The treatment
will be recommended as promising if the p-value is ≤0.1.
The overall type I error rate for monotherapy arms is
20%; the overall power is 92% when p = 0.5. The ‘overall
type I error rate’ for an arm is defined as the probability
of an inefficacious arm (p < =0.2) having its null hypoth-
esis rejected. This is the sum of the probabilities of
meeting an efficacy stopping rule after stage 1 or 2 and
reaching the final analysis and having a final p-value of
≤0.1. The overall power is this sum of probabilities when
the arm is efficacious (p = 0.5).
Although 20% type I error rate is higher than trad-
itional in phase II, each monotherapy is tested again
within the combination IMP arms.
Combination IMP arms Arm 2 Cediranib þOlaparib½ ;ð
Arm 5 Olaparibþ Durvalumab½ Þ
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Each combination arm will enrol a maximum of 20
evaluable participants with interim analyses after 10
and 15 evaluable participants have primary outcome
data available The null hypothesis is 30% or less of par-
ticipants show a response on the primary outcome. The
alternative hypothesis is that more than 30% of partici-
pants show a response:
H0: p ≤ 0.3
H1: p > 0.3
with the power calculated as the probability of reject-
ing H0 when p = 0.6.
The combination will be recommended as promising
(null hypothesis rejected) if the arm stops after stage 1
or 2 for efficacy (see Interim Analyses). If the combin-
ation continues to stage 3, a p-value will be found by
calculating the tail probability of seeing that many or
more responses if the distribution were binomial with
p = 0.3. The IMP will be recommended as promising if
the p-value is ≤0.05.
The overall type I error rate for combination IMP
arms is 10%; the overall power is 93% when p = 0.6.
Simulation code in R to recreate the statistical proper-
ties is provided as Additional file 1.
Interim analyses
Interim data analyses at predefined points will decide
whether the recruitment of additional patients into an
arm should occur. The Bayesian analysis will use a Beta
(0.3, 0.7) prior for the biological response rate (the p
parameter). Through updating this prior with the ob-
served number of biological responders using a Beta-
Binomial conjugate distribution we will calculate a Beta
posterior distribution p.
For monotherapy arms, if the calculated posterior
probability of the biological response rate being above
0.2 is above 98%, the arm will be closed early for effi-
cacy. If the predictive probability that the IMP would be
found to be promising (i.e. the final one-sided p-value
would be ≤0.1) if the full enrolment of 12 was reached is
< 2%, then the arm will be closed early for futility. This
use of the posterior distribution for efficacy stopping
and predictive distribution for futility stopping is as rec-
ommended by Berry et al. [45].
For combination IMP arms, if the calculated poster-
ior probability of the biological response rate being
above 0.3 is above 98%, the arm will be closed early
for efficacy. If the predictive probability that the IMP
would be found to be promising (i.e. the final one-
sided p-value would be ≤0.05) if the full enrolment of
20 was reached is < 2%, then the arm will be closed
early for futility.
The final p-value thresholds are chosen to control the
overall type I error rate at 20% for monotherapy arms
and 10% for combination arms.
We note that the efficacy stopping rule is provided as
a recommendation to the IDMC (see Additional file 2).
The IDMC may decide that continuing to recruit partici-
pants to an arm that meets the efficacy stopping rules is
warranted. If this occurs, then the type I error rate and
power will both be lower than the aforementioned
levels.
The recruitment targets for the interim analyses are
summarised in Fig. 1. No subgroup analysis beyond the
treatment arms is planned for this trial.
Statistical methods for primary and secondary outcomes
and missing data
A Statistical Analysis Plan (SAP) will define appropriate
95% two-sided Confidence Intervals for primary and sec-
ondary endpoint quantities prior to the first interim ana-
lysis. The extent of missing data will be reported
however no imputation of missing data is planned.
Plans to give access to the full protocol, participant level-
data and statistical code
The full protocol and participant level-data will not be
made available. A more detailed description of the devel-
opment of the Bayesian adaptive statistics used in the
design of this trial will be available in an independent
publication. Statistical code will be made available upon
reasonable request.
Oversight and monitoring
Adverse event reporting and harms
Adverse events will be monitored and recorded from the
time of consent until 90 days after the last administra-
tion of IMP. Any adverse event will be recorded in the
patient notes and the eCRF. The principal investigators
will report serious adverse events (SAEs) to the chief in-
vestigator within 24 h of awareness. The chief investiga-
tor will subsequently assess SAEs for expectedness and
relatedness prior to onwards notification to the sponsor
within a further 24 h. The chief investigator will add-
itionally report SAEs to AstraZeneca within 24 h. The CI
must report suspected unexpected serious adverse reac-
tions (SUSARs) to the Medicines and Healthcare prod-
ucts Regulatory Agency (MHRA) and the ethics
committee within 7 to 15 days depending on the sever-
ity. Reporting of SAEs which are attributable to any of
the IMPs (i.e. serious adverse reactions) and SUSARs
continues beyond the 90-day monitoring period and
after withdrawal of consent by the participant, where in-
vestigators become aware of any new events.
More details on trial oversight are available in the
Additional file 2.
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Dissemination plans
The clinical and exploratory endpoints are anticipated to
be of great interest to the RCC research community due
to the novel combinations being used. The results will
be reported at major oncology conferences and then
published in high-impact journals. Patient facing publi-
cations will be made available to interested trial partici-
pants and via our website.
Discussion
Here we present an adaptive and expandable phase II
clinical trial platform to demonstrate proof-of-
mechanism for single-agent and combination treatments
in ccRCC.
The Bayesian statistics-based adaptive trial design opti-
mises the number of trial participants in each arm, en-
suring that no more participants than necessary are
recruited to demonstrate proof of mechanism or futility
of any arm [45]. This accelerates the screening of agents
and combinations. Also, the Bayesian framework allows
adjusting for the uncertainty arising from the unknown
variability of emerging endpoints in the context of new
treatments. In addition to prioritising promising treat-
ment arms for later phase clinical trials, the extensive li-
quid and tumour bio-sampling and use of advanced
imaging support the identification of new biomarkers of
response, which are an area of unmet clinical need in
RCC. The platform design of the trial also allows learn-
ing from and defining new endpoints based on accumu-
lating study data. We have previously shown the benefit
of using imaging biomarkers as part of an adaptive trial
design protocol in the assessment of patients with RCC
in the metastatic setting [46].
The window-of-opportunity design of this trial exposes
patients to the trial medication for a brief period, prior
to standard-of-care nephrectomy. While this will allow
measuring the engagement of IMPs with their biological
target, this trial is neither designed nor powered to ac-
crue evidence of long-term treatment benefit, although
there may be unmeasurable survival advantages for pa-
tients. Therefore, larger studies in patients who are not
surgical candidates will be required to investigate sur-
vival benefits of promising treatment arms. Furthermore,
the brief treatment may lead to an underestimation of
the treatment effects.
A limitation inherent to the window-of-opportunity
design is the risk of delaying standard-of-care treatment
when serious adverse reactions occur. This risk is miti-
gated by the strict inclusion criteria, close oncology
supervision to pre-empt and identify early any significant
toxicity events, and the Bayesian adaptive trial design
which leverages information gained during interim ana-
lyses to reduce the number of participants compared to
conventional trial designs. This is also an advantage
compared to other, slowly accruing window-of-
opportunity trials. The risk of delaying surgery is dis-
cussed with potential participants in detail. On the other
hand, an advantage of the window-of-opportunity design
is that it increases the possibility to detect biological
treatment effects quickly and in a small number of pa-
tients. Specifically, examining previously untreated pa-
tients who will undergo standard-of-care nephrectomy
allows the investigation of IMPs in the absence of muta-
tions induced by previous treatment(s) as well as access
to tissue at surgery for extensive translational analyses.
This is the first clinical trial we are aware of using this
pre-surgical window-of-opportunity to investigate novel
agents and combination therapies in RCC with a Bayes-
ian design. In the future, additional treatment arms may
be added to this trial. In addition to studying new sys-
temic anti-cancer agents, synergistic effects between ra-
diation therapy localised to the tumour and DDR
inhibition could be investigated.
In summary, WIRE will provide an important impetus
for future phase II/III clinical trials to prioritise treat-
ment regimens that show biological efficacy. Addition-
ally, it will be able to inform the optimal choice of
treatment response biomarkers.
Trial status
Version 3.0 of the trial protocol (05/12/2019) has re-
ceived ethical approval and is in date as of publication of
this trial protocol. Recruitment for WIRE commenced
on the 12/08/2020 and is estimated to be completed in
12/2022.
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